Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Journal of Diabetes and Its Complications
|
November 3, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
Vivian Fonseca, Bart Staels, Jerry D Morgan, et al.
Journal of Diabetes
|
December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Robert G Moses, Elizabeth Round, Yue Shentu, et al.
Circulation
|
March 7, 2007
Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress
Ling Tao, Erhe Gao, Xiangying Jiao, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
September 27, 2007
Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity
Rong Li, Wen-Qing Wang, Haifeng Zhang, et al.
The Journal of Clinical Investigation
|
April 24, 2008
Adiponectin regulates albuminuria and podocyte function in mice
Kumar Sharma, Satish Ramachandrarao, Gang Qiu, et al.
BMC Endocrine Disorders
|
April 24, 2010
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman, Samuel S Engel, Elizabeth Round, et al.
Circulation
|
February 4, 2009
AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin
Yajing Wang, Erhe Gao, Ling Tao, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
January 29, 2013
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial
Juan C Arjona Ferreira, Dalila Corry, Carl E Mogensen, et al.
Current Medical Research and Opinion
|
March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai, Hua Guo, Erin M Mahoney, et al.
Circulation Research
|
May 3, 2008
Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell-cell adhesions in endothelial cells
Yoshimasa Nakamura, Nikolay Patrushev, Hyoe Inomata, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Journal of Diabetes and Its Complications
|
November 3, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
Vivian Fonseca, Bart Staels, Jerry D Morgan, et al.
Journal of Diabetes
|
December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Robert G Moses, Elizabeth Round, Yue Shentu, et al.
Circulation
|
March 7, 2007
Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress
Ling Tao, Erhe Gao, Xiangying Jiao, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
September 27, 2007
Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity
Rong Li, Wen-Qing Wang, Haifeng Zhang, et al.
The Journal of Clinical Investigation
|
April 24, 2008
Adiponectin regulates albuminuria and podocyte function in mice
Kumar Sharma, Satish Ramachandrarao, Gang Qiu, et al.
BMC Endocrine Disorders
|
April 24, 2010
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman, Samuel S Engel, Elizabeth Round, et al.
Circulation
|
February 4, 2009
AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin
Yajing Wang, Erhe Gao, Ling Tao, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
January 29, 2013
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial
Juan C Arjona Ferreira, Dalila Corry, Carl E Mogensen, et al.
Current Medical Research and Opinion
|
March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai, Hua Guo, Erin M Mahoney, et al.
Circulation Research
|
May 3, 2008
Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell-cell adhesions in endothelial cells
Yoshimasa Nakamura, Nikolay Patrushev, Hyoe Inomata, et al.
Page
of 8